Specificity of an Assay Based on a Factor V-depleted Plasma in Patients Carrying the Arg 506 GIn Mutation

M Alhenc-Gelas; M F Aillaud; M N Bonvarlet; G Dupuy; I Juhan-Vague; M Aiach

doi:10.1055/s-0038-1650407

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1996; 75(06): 976-977
DOI: 10.1055/s-0038-1650407

Original Article

Schattauer GmbH Stuttgart

Specificity of an Assay Based on a Factor V-depleted Plasma in Patients Carrying the Arg 506 GIn Mutation

M Alhenc-Gelas

¹The Laboratoire d’Hémostase, Hôpital Broussais, Paris

,

M F Aillaud

²Laboratoire d’Hématologie, Hôpital La Timone, Marseille

,

M N Bonvarlet

³R & D Hémostase, Société bio Mérieux, Marcy-1’Etoile, France

,

G Dupuy

³R & D Hémostase, Société bio Mérieux, Marcy-1’Etoile, France

,

I Juhan-Vague

²Laboratoire d’Hématologie, Hôpital La Timone, Marseille

,

M Aiach

¹The Laboratoire d’Hémostase, Hôpital Broussais, Paris

› Author Affiliations

Abstract

PDF Download

PDF (206 kb)

References

References
1 Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
2 Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506
3 Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
4 Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-1993
5 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
6 Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
7 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-886
8 Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 3120-3126
9 Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163
10 Trossaert M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane D. Modified resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709-1710
11 Tosetto A, Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 1995; 73: 732-733
12 Cadroy Y, Sié P, Alhenc-Gelas M, Aiach M. Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants. Thromb Haemost 1995; 73: 734
13 Dahlback B. Modified APC-resistance test offers increased sensitivity and specificity for the FV:Q506 allele. Thromb Haemost 1995; 74: 1380-1381
14 Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport S. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 1995; 85: 1704-1711
15 Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 Gin mutation. Blood Coag Fibrinol 1995; 6: 245-249